TransCode Therapeutics In...

0.40
0.00 (0.35%)
At close: Apr 11, 2025, 3:59 PM
0.39
-1.81%
After-hours: Apr 11, 2025, 05:57 PM EDT
0.35%
Bid 0.39
Market Cap 9.34M
Revenue (ttm) 753.15K
Net Income (ttm) -14.93M
EPS (ttm) 5867.6
PE Ratio (ttm) n/a
Forward PE -2.23
Analyst Buy
Ask 0.4
Volume 1,046,704
Avg. Volume (20D) 7,354,883
Open 0.38
Previous Close 0.40
Day's Range 0.37 - 0.40
52-Week Range 0.34 - 66.33
Beta 1.52

About RNAZ

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inh...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 8, 2021
Employees 8
Stock Exchange NASDAQ
Ticker Symbol RNAZ
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for RNAZ stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 4898.75% from the latest price.

Stock Forecasts

Next Earnings Release

TransCode Therapeutics Inc. is scheduled to release its earnings on Apr 25, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
-5.77%
TransCode Therapeutics shares are trading higher a... Unlock content with Pro Subscription
2 weeks ago
+2373.93%
TransCode Therapeutics shares are trading lower after the company announced a $10 million registered direct offering.